Перевести на Переведено сервисом «Яндекс.Перевод»

FDA Calendar

Date PDUFA table FDA is very important, because they help you to watch when decisions on main areas will be announced. In addition, as a rule, such reviews make it possible to anticipate key events and their development. Thus, the presence of prior knowledge of the catalyst provides a way to maximize profits or minimize losses trading in the stock of biotechnology companies.
Date Company Event Description Result
Genocea Biosciences PHASE 2 GEN-004, universal vaccine agains pneumococcus Failure
Protalix BioTherapeutics PHASE 1/2 PRX-102, Fabry disease Success
PTC Therapeutics PHASE 3 ATALUREN, Duchenne muscular dystrophy Success
Lipocine NDA FILING LPCN 1021, low testosteron Success
Radius Health NDA FILING ABALOPARATIDE-SC, osteoporosis Success
Neurocrine Biosciences PHASE 3 VMAT2 NBI-98854 - KINECT 3, tardive dyskinesia Success
Spark Therapeutics PHASE 3 SPK-RPE65, inherited retinal dystrohies Success
Amicus Therapeutics NDA FILING MIGALASTAT, Fabry disease Failure
Synthetic Biologics PHASE 2 SYN-004 (C-IBS) Failure
Verastem Phase 2 VS-6063, Pleural mesothelioma Failure
Puma Biotechnology PHASE 2 PB272, breast cancer Success
Heron Therapeutics PHASE 2 HTX-011, post-operative pain Success
ADMA Biologics BLA FILING RI-002, immune deficiency diseases Success
Heat Biologics PHASE 2 HS-110, cell lung Success
TRACON Pharmaceuticals PHASE 2 TRC105, hepatocelluar carcinoma Success
Aerie Pharmaceuticals Phase 3 Rhopressa, Glaucoma & ocular hypertension Success
Apricus Biosciences PHASE 2A RAYVA, secondary Raynaud's phenomenon Success
GW Pharmaceuticals PHASE 2 GWP42003, Schizophrenia Success
Raptor Pharmaceuticals PHASE 2 RP-103, fatty liver disease Failure
Sangamo Biosciences PHASE 2 SB-728-1401, HIV/AIDS Success
1 2